FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a method of preventing or treating chronic obstructive pulmonary disease, including the introduction of a therapeutically effective amount of a compound described by the following chemical formula I, or its pharmaceutically acceptable salts, the use of a compound described by the following chemical formula I, or its pharmaceutically acceptable salts to prevent or treatment of chronic obstructive pulmonary disease; and for the manufacture of a medicament for the treatment of chronic obstructive pulmonary disease.
(Chemical formula 1)
EFFECT: invention expands the arsenal of methods of the treatment of chronic obstructive pulmonary disease.
8 cl, 6 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SULFAMIDE COMPOUNDS OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND METHOD OF INHIBITION OF ET RECEPTORS | 1994 |
|
RU2141953C1 |
| PHARMACEUTICAL COMPOSITION INCLUDING A HISTONE DEACETYLASE INHIBITOR AND METHOTREXATE | 2019 |
|
RU2772018C1 |
| COMPOSITIONS FOR PREVENTION OR TREATMENT OF LUPUS | 2018 |
|
RU2757014C1 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2681211C2 |
| IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2696275C1 |
| COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF DRY EYES | 2019 |
|
RU2763423C1 |
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2697090C1 |
| PYRIMIDINE DERIVATIVES AND USE THEREOF IN TREATING RESPIRATORY DISEASES, SUCH AS COPD | 2011 |
|
RU2604719C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2668952C2 |
